| Resumen |
- Antecedentes: Publicaciones no científicas reportan eficacia de la forskolina por vía oral para prevenir las crisis asmáticas pues tiene efecto broncodilatador, antiinflamatorio y antioxidante. Objetivo: Determinar la eficacia de la forskolina en la prevención de crisis asmática del paciente pediátrico y del adulto. Pacientes y Métodos: 40 pacientes con asma leve o moderada persistente fueron admitidos al estudio, asignados aleatoriamente al tratamiento: (1) forskolina vía oral (10mg/día), (n=20) o (2) cromoglicato de sodio (2 inhalaciones cada 8 h.), (n=20). Determinamos número de crisis asmáticas en el último año previo al estudio (p= 0.41). VEF1 basal 2.4 0.42L y 2.2 0.70L. (p = 0.20) y FEF 25-75 porciento (p=0.2) respecto del basal, ocurriendo lo mismo en el grupo control: VEF1 (p= 0.03) y FEF25-75 porciento (p=0.005). Comparando ambos grupos, no encontramos diferencia significativa para ambas pruebas de función pulmonar: VEF1 (p= 0.20) y FEF25-75 porciento (p = 0.26). Conclusión: La forskolina es más eficaz que el cromoglicato de sodio en la prevención de las crisis asmáticas en pacientes con asma leve o moderada persistente. Antecedents: Previous studies non-scientific have reported effectiveness of the forskolin given orally for preventing asthmatic crises since it has shown a bronchodilator, antiinflamatory and antioxidant effect. Objective: To determine the effectiveness of the forskolin in the prevention of the asthmatic crisis in pediatric and adult patients. Patient and methods: 40 patients with persistent light or moderate asthma were included in the study, randomly assigned for treatments (1): forskolin (10mg/day/orally), (n=20) o (2): sodium cromoglicate (2 inhalations each 8h), (n=20). The number of asthmatic crisis was determined in the last year previous to the study (p=0.4); VEF1 basal: 2.4 - 0.42 and 2.2 - 0.70 (p=0.2) and FEF25-75 percent basal: 1.7 - 0.6 and 1.4 - 0.9 (p=0.06), for treatments 1 and 2 respectively. The VEF1, FEF25-75 percent, and the number of crisis that the patients presented during the study were determined every 15 days. There was no statistically significative difference for age, weight, height and sex. Results: We observed a greater reduction in the number of asthmatic crisis among the forskolina group (p=0.007). There was also an increase in VEF1 (p=0.01) and FEF25-75 percent (p=0.2) in study group as well as in group control: VEF1 (p = 0.03 and FEF25-75 percent (p=0.005). Attending to pulmonary function tests we found no statistically significative difference in both groups: VEF1 (p=0.2) and FEF25-75 percent (p=0.26). Conclusion: Forskolin is an useful drug in preventing asthmatic crisis in patients with persistent mild or moderated asthma. |
Tesis de posgrado